RAPT Therapeutics (NASDAQ:RAPT) Raised to Hold at Wall Street Zen

RAPT Therapeutics (NASDAQ:RAPT) was upgraded by stock analysts at Wall Street Zen from a “sell” rating to a “hold” rating in a research note issued to investors on Thursday.

Several other research analysts have also recently weighed in on RAPT. UBS Group cut their price target on shares of RAPT Therapeutics from $2.00 to $1.00 and set a “neutral” rating on the stock in a report on Thursday. HC Wainwright upgraded shares of RAPT Therapeutics to a “strong-buy” rating and set a $6.00 price target on the stock in a report on Thursday. One research analyst has rated the stock with a sell rating, four have assigned a hold rating, one has issued a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat.com, the company currently has a consensus rating of “Hold” and an average target price of $3.00.

RAPT Therapeutics Stock Performance

RAPT Therapeutics stock opened at $1.23 on Thursday. RAPT Therapeutics has a fifty-two week low of $0.71 and a fifty-two week high of $4.60. The stock has a market cap of $162.72 million, a PE ratio of -0.44 and a beta of -0.04. The firm’s 50-day simple moving average is $0.98 and its 200 day simple moving average is $1.18.

RAPT Therapeutics (NASDAQ:RAPT) last released its quarterly earnings results on Thursday, May 8th. The company reported ($0.08) earnings per share for the quarter, topping the consensus estimate of ($0.31) by $0.23. As a group, analysts predict that RAPT Therapeutics will post -2.14 EPS for the current fiscal year.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in RAPT. Medicxi Ventures Management Jersey Ltd purchased a new position in RAPT Therapeutics in the fourth quarter valued at about $35,316,000. TCG Crossover Management LLC purchased a new position in RAPT Therapeutics in the fourth quarter valued at about $19,751,000. Orbimed Advisors LLC purchased a new position in RAPT Therapeutics in the fourth quarter valued at about $20,754,000. Foresite Capital Management VI LLC purchased a new position in RAPT Therapeutics in the fourth quarter valued at about $19,750,000. Finally, RTW Investments LP purchased a new stake in shares of RAPT Therapeutics during the 4th quarter valued at approximately $18,587,000. 99.09% of the stock is currently owned by hedge funds and other institutional investors.

About RAPT Therapeutics

RAPT Therapeutics, Inc, a clinical-stage immunology-based biopharmaceutical company, focuses on discovery, development, and commercialization of oral small molecule therapies for patients with unmet needs in oncology and inflammatory diseases in the United States. The company's lead inflammation drug candidate is zelnecirnon (RPT193), a C-C motif chemokine receptor 4 (CCR4) antagonist that selectively inhibit the migration of type 2 T helper cells into inflamed tissues.